Findings

What do systematic reviews say?

6 questions · 6 findings · 5 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 0 · 0%High 1 · 16.7%

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Progression‐free survival · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
HR 0.9 [0.78, 1.04]
11 studies · 4014 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival · women with advanced or recurrent endometrial cancer

mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.43 [1.06, 1.93]
1 study · 231 participants
Low

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).

1 finding from 1 review

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes only
HR 0.68 [0.51, 0.88]
5 studies · 1886 participants
Low

Combined immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

The review found no eligible studies for this question.

1 finding from 1 review

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

EGFR tyrosine kinase inhibitor (TKI) vs observation

Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 1.05 [0.9, 1.23]
1 study · 835 participants
Very low

Afatinib vs chemotherapy alone

Progression‐free survival · EGFR M+ patients with NSCLC

Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.42 [0.34, 0.53]
2 studies · 709 participants
High